Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Glioma: early-phase trial registry
2 of 4 indexed Diffuse Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Diffuse Glioma: 4 US clinical trials tracked, 2 recruiting.
Diffuse Glioma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Nerviano Medical Sciences, running 1 of these trials.
Enrollment posture brief
Registry condition diffuse-glioma
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Diffuse Glioma lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Glioma is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
18F-Fluciclovine PET-MRI in High-grade Glioma
Children's Hospital of Philadelphia
NCT05553041
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
NCT05717153
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
NCT04910022
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
NCT04145115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Glioma page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Diffuse Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nerviano Medical Sciences sponsors the most Diffuse Glioma trials on record, review their full trial history before evaluating a specific study. See Nerviano Medical Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Glioma condition card totals 4 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.